Symbols

IGC

IGC Pharma·AMEX

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IGC

Igc Pharma, Inc.

A biotech company that develops and commercializes cannabis-based therapies for various medical conditions

Industry

Pharmaceutical

Established Date

04/29/2005

Listing Date

02/27/2019

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.igcinc.us

Security Type

Common stock

Office address

10224 Falls Road, Potomac, Maryland 20854

Business

Introduction

IGC Pharma, Inc., a Maryland corporation, was established on April 29, 2005. The company is a clinical-stage biotechnology company focused on the development of novel therapies for neuropsychiatric and neurodegenerative diseases, primarily for Alzheimer's disease. Its lead drug candidate, IGC-AD 1, is in Phase 2 trials for Alzheimer's dementia agitation, while an artificial intelligence data platform for research support is also being developed.

Company Financials

EPS

IGC has released its 2026 Q2 earnings. EPS was reported at -0.02, versus the expected -0.02, meeting expectations. The chart below visualizes how IGC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IGC has released its 2026 Q2 earnings report, with revenue of 191.00K, reflecting a YoY change of -53.64%, and net profit of -1.82M, showing a YoY change of -6.06%. The Sankey diagram below clearly presents IGC's revenue sources and cost distribution.